Femasys Secures Category III CPT Code for FemaSeed ITI, Effective Jan 2027
Femasys has secured AMA CPT Editorial Panel approval for a new Category III code covering FemaSeed intratubal insemination, effective January 1, 2027. The code advances reimbursement strategy to support broader clinical adoption and patient access for over 10 million U.S. women affected by infertility.
1. AMA CPT Code Approval
Femasys received formal approval from the AMA CPT Editorial Panel for a unique Category III CPT code specifically covering the FemaSeed intratubal insemination procedure. This code will be publicly issued with an effective date of January 1, 2027, establishing a defined billing pathway for the technology.
2. Reimbursement Strategy and Commercialization
The new CPT code is designed to advance Femasys’ reimbursement strategy by facilitating broader provider billing, accelerating clinical adoption, and expanding patient access. Femasys plans a targeted rollout to gynecologists and clinical teams, leveraging its FemSperm product line to support procedural integration.
3. Clinical Efficacy and Patient Impact
In its pivotal trial (NCT0468847), FemaSeed achieved more than double the pregnancy rates of traditional intrauterine insemination in cases of low male sperm count. Authorized for use in the U.S., Europe, UK, Canada, and Israel, the technology addresses a potential first-step infertility treatment for over 10 million U.S. women.